These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8698504)

  • 1. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.
    van der Voort ER; van der Ley P; van der Biezen J; George S; Tunnela O; van Dijken H; Kuipers B; Poolman J
    Infect Immun; 1996 Jul; 64(7):2745-51. PubMed ID: 8698504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.
    Martin DR; Ruijne N; McCallum L; O'Hallahan J; Oster P
    Clin Vaccine Immunol; 2006 Apr; 13(4):486-91. PubMed ID: 16603616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.
    Wedege E; Kuipers B; Bolstad K; van Dijken H; Frøholm LO; Vermont C; Caugant DA; van den Dobbelsteen G
    Infect Immun; 2003 Jul; 71(7):3775-81. PubMed ID: 12819059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; Kuipers AJ; van Limpt CJ; Keijzers WC; van der Ende A; de Groot R; van Alphen L; van den Dobbelsteen GP
    Infect Immun; 2003 Apr; 71(4):1650-5. PubMed ID: 12654777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.
    Boutriau D; Poolman J; Borrow R; Findlow J; Domingo JD; Puig-Barbera J; Baldó JM; Planelles V; Jubert A; Colomer J; Gil A; Levie K; Kervyn AD; Weynants V; Dominguez F; Barberá R; Sotolongo F
    Clin Vaccine Immunol; 2007 Jan; 14(1):65-73. PubMed ID: 17065257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.
    Moe GR; Zuno-Mitchell P; Hammond SN; Granoff DM
    Infect Immun; 2002 Nov; 70(11):6021-31. PubMed ID: 12379678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread.
    Jelfs J; Munro R; Wedege E; Caugant DA
    Clin Diagn Lab Immunol; 2000 May; 7(3):390-5. PubMed ID: 10799451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.
    Naess LM; Oftung F; Aase A; Wetzler LM; Sandin R; Michaelsen TE
    Infect Immun; 1998 Mar; 66(3):959-65. PubMed ID: 9488382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.
    Sadarangani M; Hoe JC; Callaghan MJ; Jones C; Chan H; Makepeace K; Daniels-Treffandier H; Deadman ME; Bayliss C; Feavers I; van der Ley P; Pollard AJ
    PLoS One; 2012; 7(12):e51045. PubMed ID: 23251421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.
    Hung MC; Salim O; Williams JN; Heckels JE; Christodoulides M
    Infect Immun; 2011 Sep; 79(9):3784-91. PubMed ID: 21708989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular immune responses to Neisseria meningitidis in children.
    Pollard AJ; Galassini R; Rouppe van der Voort EM; Hibberd M; Booy R; Langford P; Nadel S; Ison C; Kroll JS; Poolman J; Levin M
    Infect Immun; 1999 May; 67(5):2452-63. PubMed ID: 10225908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease.
    Kyaw MH; Clarke SC; Christie P; Jones IG; Campbell H
    J Clin Microbiol; 2002 May; 40(5):1834-7. PubMed ID: 11980971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.
    Mehta OH; Norheim G; Hoe JC; Rollier CS; Nagaputra JC; Makepeace K; Saleem M; Chan H; Ferguson DJ; Jones C; Sadarangani M; Hood DW; Feavers I; Derrick JP; Pollard AJ; Moxon ER
    PLoS One; 2014; 9(12):e115713. PubMed ID: 25545241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response.
    Steeghs L; Kuipers B; Hamstra HJ; Kersten G; van Alphen L; van der Ley P
    Infect Immun; 1999 Oct; 67(10):4988-93. PubMed ID: 10496868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST database.
    Watkins ER; Maiden MC
    PLoS One; 2012; 7(9):e45349. PubMed ID: 23028953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing of the porB gene: a step toward a true characterization of Neisseria meningitidis.
    Abad R; Alcalá B; Salcedo C; Enríquez R; Uría MJ; Diez P; Vázquez JA
    Clin Vaccine Immunol; 2006 Oct; 13(10):1087-91. PubMed ID: 17028211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of the PorB protein in serotype 22 Neisseria meningitidis.
    Urwin R; Fox AJ; Musilek M; Kriz P; Maiden MC
    J Clin Microbiol; 1998 Dec; 36(12):3680-2. PubMed ID: 9817895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple mechanisms of phase variation of PorA in Neisseria meningitidis.
    van der Ende A; Hopman CT; Dankert J
    Infect Immun; 2000 Dec; 68(12):6685-90. PubMed ID: 11083782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PorA variable regions of Neisseria meningitidis.
    Russell JE; Jolley KA; Feavers IM; Maiden MC; Suker J
    Emerg Infect Dis; 2004 Apr; 10(4):674-8. PubMed ID: 15200858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of the Immunomodulatory Effects of Meningococcal Opa Proteins on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells.
    Jones C; Sadarangani M; Lewis S; Payne I; Saleem M; Derrick JP; Pollard AJ
    PLoS One; 2016; 11(4):e0154153. PubMed ID: 27111850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.